WO2016072710A1 - Tranquilizing composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata - Google Patents
Tranquilizing composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata Download PDFInfo
- Publication number
- WO2016072710A1 WO2016072710A1 PCT/KR2015/011718 KR2015011718W WO2016072710A1 WO 2016072710 A1 WO2016072710 A1 WO 2016072710A1 KR 2015011718 W KR2015011718 W KR 2015011718W WO 2016072710 A1 WO2016072710 A1 WO 2016072710A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- culture medium
- laccerata
- extracellular polysaccharide
- weight
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000004480 active ingredient Substances 0.000 title claims abstract description 15
- 241001466515 Emmia lacerata Species 0.000 title claims abstract description 8
- 229920002444 Exopolysaccharide Polymers 0.000 title abstract description 4
- 230000002936 tranquilizing effect Effects 0.000 title abstract 4
- 239000001963 growth medium Substances 0.000 claims abstract description 51
- 239000000843 powder Substances 0.000 claims abstract description 34
- 150000004676 glycans Chemical class 0.000 claims description 52
- 229920001282 polysaccharide Polymers 0.000 claims description 52
- 239000005017 polysaccharide Substances 0.000 claims description 52
- 241000123410 Ceriporia Species 0.000 claims description 26
- 235000000346 sugar Nutrition 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 235000013376 functional food Nutrition 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 238000009630 liquid culture Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 235000019764 Soybean Meal Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000004455 soybean meal Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 240000006394 Sorghum bicolor Species 0.000 claims 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 abstract description 8
- 230000036506 anxiety Effects 0.000 abstract description 8
- 235000013402 health food Nutrition 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000001965 potato dextrose agar Substances 0.000 description 12
- 239000011575 calcium Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000000971 hippocampal effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000005227 gel permeation chromatography Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- 102000018899 Glutamate Receptors Human genes 0.000 description 4
- 108010027915 Glutamate Receptors Proteins 0.000 description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- -1 hydrate Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
Definitions
- the present invention relates to an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ) or a mycelial culture solution of Ceriporia laccerata comprising the same, a dry powder or extract thereof as an active ingredient .
- the main organs involved are the cerebral limbic system (especially the hippocampus and the subject society), the cerebral cortex (frontal lobe, temporal lobe), hypothalamus, ascending reticular body and pituitary gland.
- cerebral cortex frontal lobe, temporal lobe
- hypothalamus ascending reticular body and pituitary gland.
- Recent brain imaging studies have shown that anxiety is associated with disorders in the right hemisphere and other frontal, temporal, and occipital lobe disorders (Robert F. Scmidt, Human physiology , pp. 366; -40).
- the study of therapeutic drugs for anxiety has attracted interest in the development of new drugs, especially glutamate receptor inhibitors, as well as the reevaluation of old drugs and the expansion of indications.
- An ideal neurostabilizer is one that does not cause excessive drowsiness during the daytime, does not cause physical and mental dependence, and calms the patient.
- Representative neurostabilizers currently available are benzodiazepine, diazepam, oxazepam, prazepam, lorazepam, alprazolam, helazepam, clona Such as clonazepam, and these drugs are also used for the purpose of sedation and sleep (Yoon Do Joon, Side Effects of Psychiatric Drugs, Journal of the Korean Medical Association, 38 (10), pp.1196-1202, 1995).
- Benzodiazepines are the most commonly used neurostabilizers and are known to increase the affinity of GABA receptors, which are representative inhibitory neurotransmitters in the central nervous system, thus opening adjacent Cl ⁇ channels more often to increase the permeability of Cl ⁇ ions.
- This benzodiazepine is effective immediately, but due to habits and addictions, symptoms may recur or withdraw if the drug is not used according to a specialist's treatment.
- Other side effects include drowsiness, ataxia, orthostatic hypotension, respiratory depression, headache, and chronic sleep. Disorders, liver disease and the like have been reported (Mary J. Mycek et al. , Pharmacology 2nd edition, Lipincott Williams & Wilkins, pp. 89-93, 2000). Therefore, the research to develop a neurostable material with no side effects has been actively conducted.
- Ceriporia laccerata is a type of white fungus and is known to perform cometabolism called lignin decomposition in order to use carbon sources such as cellulose, hemicellulose, other polysaccharides, and glycerol in an ecosystem.
- lignin decomposition cometabolism
- carbon sources such as cellulose, hemicellulose, other polysaccharides, and glycerol
- Seriforia Lakseratta was first reported to academics in 2002, the study of its industrialization is still incomplete.
- the present inventors have found that the mycelium culture medium, the dry powder or extract thereof of the extracellular polysaccharide produced by Seriphoria laccerata or the same, including the same, have a neurostable effect, which is used as an active ingredient.
- the present invention relating to a neurostable composition is completed.
- An object of the present invention is to provide a neurostable composition containing a pharmacologically active ingredient produced by Ceriporia laccerata.
- Still another object of the present invention is to provide a health functional food having a neurostable effect containing a pharmacologically active ingredient produced by Ceriporia laccerata.
- the present invention is an extracellular polysaccharide produced by Seriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a neurostable composition containing the extract of the mycelia culture medium as an active ingredient.
- the present invention is an extracellular polysaccharide produced by Seriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a health functional food having neurostable efficacy containing the extract of the mycelia culture medium as an active ingredient.
- the present invention is an extracellular polysaccharide produced by Seriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a neurostable method comprising administering the extract of the mycelium culture to a subject in need of neurostable.
- the present invention is an extracellular polysaccharide produced by Ceriporia laccerata for use in the manufacture of a medicament for neurostable; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a use of the extract of the mycelium culture.
- 1 is a graph showing the change rate (% inhibition) of intracellular calcium concentration when the EPS concentration is 100 ug / mL.
- the present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ); Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a neurostable composition containing the extract of the mycelia culture medium as an active ingredient.
- the extracellular polysaccharide is about 40 to 60% by weight sugar and about 30 to 40% by weight protein, about 40 to 50% by weight sugar and about 32 to 38% by weight protein, or It may comprise about 43 to 47% by weight of sugar and about 33 to 36% by weight of protein, preferably about 45% by weight of sugar and about 34% by weight of protein.
- the sugar may contain mannose, galactose and glucose.
- the extracellular polysaccharide may have a molecular weight of about 100 to 150 kDa, about 110 to 140 kDa or about 115 to 125 kDa, and preferably may have a molecular weight of about 120 kDa.
- the extracellular polysaccharide in one preferred embodiment, the extracellular polysaccharide,
- the medium for the liquid culture of the seriporia laccerata mycelium in the step (a) is sugar, glucose, starch, hydrate, soybean meal, soybean meal, magnesium sulfate (MgSO 4 ), potassium phosphate (KH 2 PO 4 ), potassium diphosphate (K 2 HPO 4 ) and water, the hydrogen ion concentration (pH) may be 4.5 to 6.0.
- the medium 0.2-3% by weight sugar, 0.2-3% by weight glucose, 0.2-4% by weight starch, 0.1-0.5% by weight moisture, 0.1-0.5% by weight wheat flour, soybean meal 0.2 to 3% by weight, 0.05 to 0.1% by weight of magnesium sulfate (MgSO 4 ), 0.05 to 0.25% by weight of potassium monophosphate (KH 2 PO 4 ), 0.05 to 0.25% by weight of potassium diphosphate (K 2 HPO 4 ) May comprise water.
- MgSO 4 magnesium sulfate
- KH 2 PO 4 potassium monophosphate
- K 2 HPO 4 potassium diphosphate
- the liquid culture in step (a) may be performed under a blue LED light source, and may be performed by maintaining a concentration of carbon dioxide at 1,000 to 2,000 ppm.
- the liquid culture for example, at 20 ⁇ 25 °C, hydrogen ion concentration (pH) 4.5 ⁇ 6.0, light source blue LED, illuminance maintains 0.5 LUX and air is injected into 0.5 ⁇ 1.5 kgf / cm 2 and carbon dioxide It can be carried out for 8 to 13 days while maintaining the concentration of 1,000 to 2,000 ppm, it is preferable to be carried out for 10 days at 22 °C, pH 5.0, 1.0 kgf / cm 2 , 1,500 ppm conditions because the content of the extracellular polysaccharide is high. .
- one excellent strain stored at 4 ° C. in a PDA (Potato dextrose agar) medium state was used at 25 ° C. in a shaker incubator using PDB (Potato dextrose broth) medium in an Erlenmeyer flask. It can be used to maintain a constant temperature and after 7 to 9 days incubation process.
- the amount of mycelia to be added to the inoculum is preferably about 0.5% (w / v) based on the amount of the solution to be cultured.
- the medium composition is a selective culture condition that forms the highest content of extracellular polysaccharides rather than the best nutritional ratio and environmental conditions for growth of the mycelia. It is preferable to apply.
- the culture solution can be separated and purified into a mycelium and an aqueous solution.
- the solution from which the mycelium is removed by centrifugation may be repeatedly purified using a multi-sheet filter press and a vibration centrifugal separator (PALLSEP), and then irradiated with ultraviolet (UV) light for 1 minute.
- PALLSEP vibration centrifugal separator
- UV ultraviolet
- the solution needs to be kept sealed after removing oxygen, because if the mycelium is present in the solution, the mycelium grows by oxygen, which brings about a change in the content of the active ingredient.
- the mycelia culture solution prepared in step (a) may be powdered by vacuum drying or lyophilization.
- the drying is preferably carried out for 48 to 96 hours at a temperature of 40 °C or less, preferably 30 °C or less in order to prevent the disappearance of the active material.
- drying in step (b) is preferable to use a vacuum freeze dryer rather than a vacuum dryer to set the evaporation temperature relatively high because the change in the effective material content is minimized.
- step (c) after extracting the dry powder of the mycelium culture medium obtained in step (b) with a solvent to separate and prepare an extracellular polysaccharide which is an active ingredient of the composition according to the present invention. Specifically, 100 g of dry powder was added and 100 mL of distilled water was suspended, followed by centrifugation (8,000 rpm, 20 min) to add an extraction solvent corresponding to 2 to 3 times the amount of the supernatant thereof and a refrigerator (4 ° C). ) Can be left for 12 hours. After centrifugation (8,000 rpm, 20 min) again only the supernatant from the stationary material, the precipitate may be recovered to prepare crude extracellular polysaccharide. It is preferable to freeze-dry the crude extracellular polysaccharide at 30 ° C or lower.
- the extraction solvent may be a solvent selected from the group consisting of water, ethanol, methanol, acetone, butanol and ethyl acetate or a mixed solvent thereof, preferably water or 50% (w / w) to 80% (w) / w) aqueous ethanol solution.
- Extracellular polysaccharide produced by the seriporia laccerata according to the present invention Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium;
- the neurostable composition containing the extract of the mycelium culture medium as an active ingredient may further include appropriate carriers, excipients, and diluents commonly used.
- the extracellular polysaccharide may be included in 0.1 to 80% by weight, preferably 0.1 to 50% by weight based on the total weight of the composition, the mycelium culture medium, dry powder or extract thereof of the Seriphoria laccerata content of the extracellular polysaccharide It may be appropriately included in the amount corresponding to. However, the effective amount of the most preferred extracellular polysaccharide or the culture solution containing the same, its dry powder or extract can be appropriately adjusted according to the method of use and purpose of the composition.
- compositions according to the invention can each be formulated and used according to conventional methods. Suitable formulations include, but are not limited to, tablets, pills, powders, granules, dragees, hard or soft capsules, solutions, suspensions or emulsions, injections, suppositories, and the like.
- composition according to the invention can be prepared in a suitable formulation using a pharmaceutically inert organic or inorganic carrier. That is, lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof may be used when the formulation is a tablet, coated tablet, dragee and hard capsule.
- a pharmaceutically inert organic or inorganic carrier that is, lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof may be used when the formulation is a tablet, coated tablet, dragee and hard capsule.
- polyols of vegetable oils, waxes, fats, semisolids and liquids can be used.
- water, polyols, glycerol, vegetable oils and the like can be used when the formulation is in the form of a solution or syrup.
- composition according to the present invention may further include a preservative, a stabilizer, a wetting agent, an emulsifier, a solubilizer, a sweetener, a colorant, an osmotic agent, an antioxidant, and the like in addition to the above carrier.
- the method of administering the composition according to the present invention can be easily selected according to the dosage form, and can be administered orally or parenterally.
- the dosage may vary depending on the age, sex, weight, severity, and route of administration of the patient, but is generally in an amount of 5 to 500 mg / kg, preferably 100 to 250 mg / kg, based on the extracellular polysaccharide as an active ingredient.
- the amount of may be administered once to three times a day.
- the dosage does not limit the scope of the invention in any aspect.
- composition according to the present invention not only provides an excellent neurostable effect, but also has little toxicity and side effects due to the drug, so that it can be used with confidence even for long term administration for neurostable purposes.
- the compositions of the present invention can be used for the prevention and treatment of diseases requiring neurostable, such as depression, anxiety, sleep disorders, attention deficit / hyperactivity disorder (ADHD) and the like.
- diseases requiring neurostable such as depression, anxiety, sleep disorders, attention deficit / hyperactivity disorder (ADHD) and the like.
- the present invention is an extracellular polysaccharide produced by Ceriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a health functional food having neurostable efficacy containing the extract of the mycelia culture medium as an active ingredient.
- the health functional food according to the present invention may be in the form of powder, granules, tablets, capsules or beverages, and may be candy, chocolate, beverages, gums, teas, vitamin complexes, health supplements, and the like.
- the extracellular polysaccharide according to the present invention in the food or the mycelia culture solution comprising the same, dried powder or extract thereof may generally be included in 0.01 to 50% by weight, preferably 0.1 to 20% by weight of the total food weight, In the case of a health beverage composition may be included in a ratio of 0.02 to 10g, preferably 0.3 to 1g based on 100ml.
- the food is an extracellular polysaccharide produced by the seriporia laccerata of the present invention; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it may further include a food supplement acceptable food additive with the extract of the mycelia culture medium.
- the present invention is an extracellular polysaccharide produced by the seriporia lacserata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a neurostable method comprising administering the extract of the mycelium culture to a subject in need of neurostable.
- the subject requiring neurostable may be a mammalian animal, and more specifically, a human.
- the present invention also provides an extracellular polysaccharide produced by Ceriporia laccerata for use in the preparation of a medicament for neurostable; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a use of the extract of the mycelium culture.
- the neurostable method can be used for the prevention and treatment of diseases requiring neurostable, for example, depression, anxiety, sleep disorders, attention deficit / hyperactivity disorder (ADHD).
- diseases requiring neurostable for example, depression, anxiety, sleep disorders, attention deficit / hyperactivity disorder (ADHD).
- ADHD attention deficit / hyperactivity disorder
- the light source After inoculating 600 ml of the PDB culture strain with a starter in a state of cooling to 23 ° C., while ventilating air at 0.5 to 1.5 kgf / cm 2, the light source maintains a blue LED, illuminance of 0.5 LUX, and a concentration of carbon dioxide.
- the Ceriporia laccerata mycelium was prepared by culturing the Ceriporia laccerata mycelium at 2,000 ppm for 10 days liquid culture at a constant temperature of 23 °C.
- the dry powder of the Ceriporia laccerata mycelium culture medium was prepared by pulverizing and drying the Ceriporia laccerata mycelium culture medium prepared in Preparation Example 1.1 at 25 ° C. for 72 hours using a vacuum freeze dryer.
- the EPS prepared in Preparation Example 1 was dissolved in 0.1 M Na 2 SO 4 /0.05 M NaN 3 (adjust the pH to 4 with glacial acetic acid) to 1% (w / v), and then 4,000 rpm. After centrifugation for 0.5 hours, only the supernatant was filtered with a 0.45 ⁇ m syringe filter and analyzed by GPC.
- GPC analysis conditions were used for the refractive index as a detector, GPC column was used OHpak SB 805 HQ (Shodex, Japan), mobile phase 0.1 M Na 2 SO 4 /0.05 M NaN 3 (with pH 4 as glacial acetic acid) The flow rate of the mobile phase was flowed at 1.0 mL / minute. Standard curves were prepared using Dextran (American Polymer Corporation, USA) with different molecular weights (130 kDa, 400 kDa, 770 kDa, or 1200 kDa), and Knauer K-2310 (refractive index (RI) measuring instrument). Germany) to determine the molecular weight of EPS. The measurement conditions are summarized in Table 1 below.
- the molecular weight of EPS of the present invention was found to be about 120 kDa.
- the EPS prepared in Preparation Example 1 was second-purified and treated with proteolytic enzymes to determine sugar and protein content.
- the first purified EPS (EPS prepared in Preparation Example 1) is dissolved in distilled water and centrifuged at 8,000 rpm for 20 minutes to separate the supernatant, and the amount of the supernatant is 2-3 times the amount of the separated supernatant. Ethanol was added and placed in a 4 ° C. refrigerator for 12 hours. Thereafter, only the supernatant was again centrifuged at 8,000 rpm for 20 minutes in the stationary material, and the precipitate was recovered to obtain a second purified EPS. After dissolving the second purified EPS in distilled water, the proteolytic enzyme alcalase was treated at 50 ° C. for 30 minutes at a concentration of 0.5% (w / v).
- sugar content was measured by the phenol-sulfuric acid method (phenol-sulfuric acid method). Specifically, 25 ⁇ l of 80% (v / v) phenol was added to 1 mL of the diluted sample, 2.5 mL of sulfuric acid was added, cooled to room temperature, and absorbance was measured at 465 nm to calculate sugar content.
- phenol-sulfuric acid method phenol-sulfuric acid method
- protein content was measured by the BCA method (Smith PK et al. , Analytical Biochemistry , 150 (1): 76-85, 1985) and bovine serum albumin was used as a standard.
- the sugar content and protein content measured as described above are shown in Table 2 below, and the sugar content was found to be 45 to 51 wt% and the protein content was 33 to 34 wt%.
- EPS mainly contained mannose, galactose and glucose.
- EPS isolated from Ceriporia laccerata mycelium culture medium intracellular calcium concentration after treatment of EPS prepared in Preparation Example 1 to hippocampal single cells isolated from fetal hippocampal neural tissues of rats The change was measured. Specifically, hippocampal neural tissues were isolated from fetuses of 18 to 19 days pregnant under a dissecting microscope and 0.25% trypsin was added and reacted at 37 ° C. for 10 minutes. Subsequently, the tissue was washed several times with HBSS (Hanks' Balanced Salt Solution) to remove trypsin, and the hippocampal cells were separated into single cells with a 1 ml pipette.
- HBSS Hort' Balanced Salt Solution
- the intracellular calcium concentration change is shown in Table 3 and FIG.
- EPS according to the present invention is a calcium channel while acting on the flow channel in the receptor to the low affinity antagonists (Ca + 2 channel) suppressed and the calcium ion (Ca 2+) of the glutamate receptor activity by significantly reducing the inflow cells of the active Reduced.
- the results show that the EPS according to the present invention has a neurostable effect through inhibition of glutamate (exciting neurotransmitter) receptors.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a tranquilizing composition containing as an active ingredient: exopolysaccharide produced by means of Ceriporia lacerata; a Ceriporia lacerata mycelium culture medium comprising the exopolysaccharide; dry powder of the mycelium culture medium; or an extract of the mycelium culture medium. The composition can be used as a tranquilizer for preventing or treating depression or anxiety or as a functional health food having tranquilizing effect.
Description
본 발명은 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체 또는 이를 포함하는 세리포리아 락세라타의 균사체 배양액, 이의 건조분말 또는 추출물을 유효성분으로 함유하는 신경안정용 조성물에 관한 것이다.The present invention relates to an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ) or a mycelial culture solution of Ceriporia laccerata comprising the same, a dry powder or extract thereof as an active ingredient .
최근 경제성장률과 같은 경제문제, 이혼과 자녀문제 등 다양한 원인으로 인해 우울증 또는 불안증 환자가 급증하고 있는 추세이다. 불안(anxiety)이란, 광범위하게 매우 불쾌한, 그리고 막연히 불안한 느낌으로, 관련된 신체증상(가슴 두근거림, 진땀 등)과 행동증상(과민성, 서성댐 등)을 동반하는 것이다(Robert F. Scmidt, Human physiology, pp.366; 민성길, 최신정신의학, pp.238-40; Argyropoulos S.V. et al., Pharmacol
.
Ther. 88, pp.213-27, 2000). 불안이 있을 때 뇌 전체는 각성(arousal) 상태에 들어가며, 따라서 말초의 행동, 자율신경계, 감각, 지각 등에 지장이 나타난다. 주로 관계된 기관은 대뇌 변연계(특히 해마와 대상회), 대뇌 피질(전두엽, 측두엽), 시상하부, 상행망상체, 뇌하수체 등이고 말초에서는 갑상선과 부신 피질이다. 최근 뇌 영상 연구에 의하면 불안은 오른쪽 반구의 장애와 관련되며 기타 전두엽, 측두엽, 후두엽 장애와 관련되어 있다고 알려져 있다(Robert F. Scmidt, Human physiology, pp.366; 민성길, 최신정신의학, pp.238-40). 불안에 대한 치료 약물의 연구는 오래된 약물의 재평가 및 적응증의 확대뿐만 아니라 새로운 약물의 개발, 특히 글루타메이트 수용체 억제제 등의 개발에 관심이 모아지고 있다. 또한, 해마세포 내의 칼슘농도를 감소시킬 수 있는 약물은 글루타메이트 수용체 억제제로서 작용하여 신경안정제로서 사용될 수 있음이 당 분야에 잘 알려져 있다(Pharmacological Reviews March 1., vol. 51, no. 1, pp.7-62, 1999). 그러나 임상적으로 유효한 항불안 약물들은 항불안의 효과뿐만 아니라 진정, 금단 현상 유발 등의 부작용 때문에 사용에 신중을 기해야 하는 단점이 있다고 할 수 있다.Recently, the number of patients with depression or anxiety is increasing rapidly due to various causes such as economic problems such as economic growth rate, divorce and child problems. Anxiety is a feeling of widespread, very unpleasant and vaguely disturbing feelings, accompanied by associated physical symptoms (pumping, sweating, etc.) and behavioral symptoms (such as irritability, pacing) (Robert F. Scmidt, Human physiology) , pp.366; minseonggil latest psychiatry, pp.238-40;... Argyropoulos SV et al, Pharmacol Ther 88, pp.213-27, 2000). When there is anxiety, the entire brain enters an arousal state, thus disrupting peripheral behavior, autonomic nervous system, sensations, and perception. The main organs involved are the cerebral limbic system (especially the hippocampus and the subject society), the cerebral cortex (frontal lobe, temporal lobe), hypothalamus, ascending reticular body and pituitary gland. Recent brain imaging studies have shown that anxiety is associated with disorders in the right hemisphere and other frontal, temporal, and occipital lobe disorders (Robert F. Scmidt, Human physiology , pp. 366; -40). The study of therapeutic drugs for anxiety has attracted interest in the development of new drugs, especially glutamate receptor inhibitors, as well as the reevaluation of old drugs and the expansion of indications. In addition, it is well known in the art that drugs capable of reducing calcium concentration in hippocampal cells can act as glutamate receptor inhibitors and be used as neurostabilizers (Pharmacological Reviews March 1., vol. 51, no. 1, pp. 7-62, 1999). However, clinically effective anti-anxiety drugs have the disadvantage of requiring careful use due to side effects such as sedation and withdrawal, as well as anti-anxiety effects.
이상적인 신경안정제는 낮 시간에 지나친 졸음을 초래하지 않고 육체적 정신적 의존성을 일으키지 않으며 환자를 침착하게 만드는 것이다. 현재 상용되는 대표적 신경안정제는 벤조디아제핀(benzodiazepine), 디아제팜(diazepam), 옥사제팜(oxazepam), 프라제팜(prazepam), 로라제팜(lorazepam), 알프라졸람(alprazolam), 헬라제팜(helazepam), 클로나제팜(clonazepam) 등이 있으며, 이들 약물들은 진정 및 수면유도의 목적으로도 사용된다(윤도준, 정신과 약물의 부작용, 대한의사협회지, 38(10), pp.1196-1202, 1995). 벤조디아제핀은 가장 흔히 사용되는 신경안정제로서, 중추신경계에서 대표적 억제성 신경전달물질인 GABA 수용체의 친화력을 증가시켜 인접한 Cl- 통로를 더 자주 열어 Cl- 이온의 투과성을 상승시킨다고 알려져 있다. 이 벤조디아제핀은 효과가 즉각 나타나지만 습관성과 중독성으로 인해 전문의의 치료에 따라 약을 사용하지 않으면 증상이 재발하거나 금단증상이 나타나며, 다른 부작용으로 졸음, 운동실조, 기립성 저혈압, 호흡억제, 두통, 만성수면장애, 간질환 등이 나타난다고 보고되고 있다(Mary J. Mycek et al., Pharmacology 2nd edition, Lipincott Williams & Wilkins, pp.89-93, 2000). 따라서, 부작용이 없는 신경안정물질을 개발하고자 하는 연구가 활발하게 진행되고 있다.An ideal neurostabilizer is one that does not cause excessive drowsiness during the daytime, does not cause physical and mental dependence, and calms the patient. Representative neurostabilizers currently available are benzodiazepine, diazepam, oxazepam, prazepam, lorazepam, alprazolam, helazepam, clona Such as clonazepam, and these drugs are also used for the purpose of sedation and sleep (Yoon Do Joon, Side Effects of Psychiatric Drugs, Journal of the Korean Medical Association, 38 (10), pp.1196-1202, 1995). Benzodiazepines are the most commonly used neurostabilizers and are known to increase the affinity of GABA receptors, which are representative inhibitory neurotransmitters in the central nervous system, thus opening adjacent Cl − channels more often to increase the permeability of Cl − ions. This benzodiazepine is effective immediately, but due to habits and addictions, symptoms may recur or withdraw if the drug is not used according to a specialist's treatment. Other side effects include drowsiness, ataxia, orthostatic hypotension, respiratory depression, headache, and chronic sleep. Disorders, liver disease and the like have been reported (Mary J. Mycek et al. , Pharmacology 2nd edition, Lipincott Williams & Wilkins, pp. 89-93, 2000). Therefore, the research to develop a neurostable material with no side effects has been actively conducted.
이와 관련하여, 천연물은 오래 전부터 임상적 효능이 입증되어 왔고 일반적으로 화학물질보다 부작용이 적으므로 신경안정용 조성물의 개발을 위한 적절한 후보물질이다.In this regard, natural products have been clinically proven for a long time and generally have fewer side effects than chemicals and thus are suitable candidates for the development of neurostable compositions.
세리포리아 락세라타는 백색 부후균의 일종으로서, 생태계에서 셀룰로오스, 헤미 셀룰로오스, 기타 다당류 및 글리세롤 등의 탄소원을 이용하기 위하여 리그닌 분해라는 공동대사(cometabolism)를 수행하는 것으로 알려져 있다. 그러나, 세리포리아 락세라타는 2002년 처음으로 학계에 보고된 이후 이의 산업화에 대한 연구는 아직 미비한 실정이다. Ceriporia laccerata is a type of white fungus and is known to perform cometabolism called lignin decomposition in order to use carbon sources such as cellulose, hemicellulose, other polysaccharides, and glycerol in an ecosystem. However, since Seriforia Lakseratta was first reported to academics in 2002, the study of its industrialization is still incomplete.
이에, 본 발명자들은 세리포리아 락세라타에 의해 생산되는 세포외다당체 또는 이를 포함하는 세리포리아 락세라타의 균사체 배양액, 이의 건조분말 또는 추출물이 신경안정 효과를 갖는 것을 발견하고, 이를 유효성분으로 함유하는 신경안정용 조성물에 관한 본 발명을 완성하였다.Accordingly, the present inventors have found that the mycelium culture medium, the dry powder or extract thereof of the extracellular polysaccharide produced by Seriphoria laccerata or the same, including the same, have a neurostable effect, which is used as an active ingredient. The present invention relating to a neurostable composition is completed.
본 발명의 목적은 세리포리아 락세라타에 의해 생산되는 약리 활성 성분을 함유하는 신경안정용 조성물을 제공하는 것이다. An object of the present invention is to provide a neurostable composition containing a pharmacologically active ingredient produced by Ceriporia laccerata.
본 발명의 또 다른 목적은 세리포리아 락세라타에 의해 생산되는 약리 활성 성분을 함유하는 신경안정 효능을 갖는 건강기능식품을 제공하는 것이다.Still another object of the present invention is to provide a health functional food having a neurostable effect containing a pharmacologically active ingredient produced by Ceriporia laccerata.
상기 목적을 달성하기 위하여, 본 발명은 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는 신경안정용 조성물을 제공한다.In order to achieve the above object, the present invention is an extracellular polysaccharide produced by Seriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a neurostable composition containing the extract of the mycelia culture medium as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는 신경안정 효능을 갖는 건강기능식품을 제공한다.In order to achieve the above object, the present invention is an extracellular polysaccharide produced by Seriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a health functional food having neurostable efficacy containing the extract of the mycelia culture medium as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 신경안정을 필요로 하는 대상에 투여하는 것을 포함하는, 신경안정방법을 제공한다.In order to achieve the above object, the present invention is an extracellular polysaccharide produced by Seriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a neurostable method comprising administering the extract of the mycelium culture to a subject in need of neurostable.
상기 목적을 달성하기 위하여, 본 발명은 신경안정을 위한 약제의 제조에 사용하기 위한, 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물의 용도를 제공한다.In order to achieve the above object, the present invention is an extracellular polysaccharide produced by Ceriporia laccerata for use in the manufacture of a medicament for neurostable; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a use of the extract of the mycelium culture.
본 발명에 따른 세리포리아 락세라타에 의해 생산되는 세포외다당체 또는 이를 포함하는 세리포리아 락세라타의 균사체 배양액, 이의 건조분말 또는 추출물을 유효성분으로 함유하는 조성물은 신경안정 용도로 유용하게 이용될 수 있다.Extracellular polysaccharide produced by Seriphoria laccerata according to the present invention, or a mycelium culture solution of Seriphoria laccerata comprising the same, a composition containing the dry powder or extract thereof as an active ingredient is useful for neurostable use Can be.
도 1은 EPS의 농도가 100 ug/mL일 때의 세포 내 칼슘 농도 변화비율(억제%)을 나타낸 그래프이다.1 is a graph showing the change rate (% inhibition) of intracellular calcium concentration when the EPS concentration is 100 ug / mL.
이하, 본 발명을 상세하게 설명한다. EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.
본 발명은 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는, 신경안정용 조성물을 제공한다.The present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ); Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a neurostable composition containing the extract of the mycelia culture medium as an active ingredient.
본 발명에 따른 조성물에 있어서, 상기 세포외다당체는 약 40~60 중량%의 당과 약 30~40 중량%의 단백질, 약 40~50 중량%의 당과 약 32~38 중량%의 단백질, 또는 약 43~47 중량%의 당과 약 33~36 중량%의 단백질을 포함할 수 있고, 바람직하게는 약 45 중량%의 당과 약 34 중량%의 단백질을 포함할 수 있다.In the composition according to the invention, the extracellular polysaccharide is about 40 to 60% by weight sugar and about 30 to 40% by weight protein, about 40 to 50% by weight sugar and about 32 to 38% by weight protein, or It may comprise about 43 to 47% by weight of sugar and about 33 to 36% by weight of protein, preferably about 45% by weight of sugar and about 34% by weight of protein.
상기 당은 만노오스, 갈락토오스 및 글루코오스를 함유할 수 있다. The sugar may contain mannose, galactose and glucose.
상기 세포외다당체는 약 100~150 kDa, 약 110~140 kDa 또는 약 115~125 kDa의 분자량을 가질 수 있고, 바람직하게는 약 120 kDa의 분자량을 가질 수 있다.The extracellular polysaccharide may have a molecular weight of about 100 to 150 kDa, about 110 to 140 kDa or about 115 to 125 kDa, and preferably may have a molecular weight of about 120 kDa.
바람직한 하나의 구체예로서, 상기 세포외다당체가,In one preferred embodiment, the extracellular polysaccharide,
(a) 세리포리아 락세라타 균사체를 액체 배양하여 세리포리아 락세라타 균사체 배양액을 제조하는 단계;(a) liquid culturing the Ceriporia laccerata mycelium to prepare a Ceriporia laccerata mycelium culture solution;
(b) 세리포리아 락세라타 균사체 배양액을 건조시켜 분말화하는 단계; 및(b) drying and powdering the Ceriporia laccerata mycelium culture solution; And
(c) 세리포리아 락세라타 균사체 배양액 분말을 용매로 추출한 후 이를 여과하고 감압 농축하는 단계를 포함하는 제조 방법에 의하여 제조될 수 있다.(c) extracting the Seriporia laccerata mycelium culture powder with a solvent, and then filtering and concentrating the same under reduced pressure.
상기 (a) 단계에서의 세리포리아 락세라타 균사체의 액체 배양을 위한 배지는 설탕, 포도당, 전분, 수수분, 대맥분, 대두분, 황산마그네슘(MgSO4), 1인산칼륨(KH2PO4), 2인산칼륨(K2HPO4) 및 물을 포함하고, 수소이온농도(pH)가 4.5~6.0인 것일 수 있다.The medium for the liquid culture of the seriporia laccerata mycelium in the step (a) is sugar, glucose, starch, hydrate, soybean meal, soybean meal, magnesium sulfate (MgSO 4 ), potassium phosphate (KH 2 PO 4 ), potassium diphosphate (K 2 HPO 4 ) and water, the hydrogen ion concentration (pH) may be 4.5 to 6.0.
바람직한 하나의 구체예로서, 상기 배지는, 설탕 0.2~3 중량%, 포도당 0.2~3 중량%, 전분 0.2~4 중량%, 수수분 0.1~0.5 중량%, 대맥분 0.1~0.5 중량%, 대두분 0.2~3 중량%, 황산마그네슘(MgSO4) 0.05~0.1 중량%, 1인산칼륨(KH2PO4) 0.05~0.25 중량%, 2인산칼륨(K2HPO4) 0.05~0.25 중량% 및 잔량의 물을 포함할 수 있다.As a preferred embodiment, the medium, 0.2-3% by weight sugar, 0.2-3% by weight glucose, 0.2-4% by weight starch, 0.1-0.5% by weight moisture, 0.1-0.5% by weight wheat flour, soybean meal 0.2 to 3% by weight, 0.05 to 0.1% by weight of magnesium sulfate (MgSO 4 ), 0.05 to 0.25% by weight of potassium monophosphate (KH 2 PO 4 ), 0.05 to 0.25% by weight of potassium diphosphate (K 2 HPO 4 ) May comprise water.
상기 (a) 단계에서의 액체 배양은 청색 LED 광원 하에서 수행될 수 있고, 이산화탄소의 농도를 1,000~2,000 ppm으로 유지하여 수행될 수 있다.The liquid culture in step (a) may be performed under a blue LED light source, and may be performed by maintaining a concentration of carbon dioxide at 1,000 to 2,000 ppm.
이때, 액체 배양은 예를 들어, 20~25℃에서, 수소이온농도(pH) 4.5~6.0, 광원은 청색 LED, 조도는 0.5 LUX를 유지하며 공기는 0.5~1.5 kgf/cm2으로 주입하고 이산화탄소의 농도는 1,000~2,000 ppm으로 유지하면서 8~13일간 수행될 수 있고, 22℃, pH 5.0, 1.0 kgf/cm2, 1,500 ppm 조건에서 10일간 수행되는 것이 세포외다당체의 함량이 높으므로 바람직하다. At this time, the liquid culture, for example, at 20 ~ 25 ℃, hydrogen ion concentration (pH) 4.5 ~ 6.0, light source blue LED, illuminance maintains 0.5 LUX and air is injected into 0.5 ~ 1.5 kgf / cm 2 and carbon dioxide It can be carried out for 8 to 13 days while maintaining the concentration of 1,000 to 2,000 ppm, it is preferable to be carried out for 10 days at 22 ℃, pH 5.0, 1.0 kgf / cm 2 , 1,500 ppm conditions because the content of the extracellular polysaccharide is high. .
상기 (a) 단계에서의 모균주로는 PDA(Potato dextrose agar) 배지 상태로 4℃에 보관중인 우량균주 1개를, 삼각플라스크에 PDB(Potato dextrose broth) 배지를 사용하여 진탕배양기에서 25℃의 항온을 유지하며 7~9일간 배양과정을 거친 것을 사용할 수 있다. 이때 접종원으로 투입될 균사체의 양은 배양할 용액의 양을 기준으로 0.5%(w/v) 정도인 것이 바람직하다. 균사체량(%/100ml)이 많다고 세포외다당체의 함량도 같이 높아지는 것이 아니므로 배지 조성은 균사체의 성장에 가장 양호한 영양 비율 및 환경조건이 아닌, 세포외다당체의 함량을 가장 높게 형성시키는 선택적 배양조건을 적용하는 것이 바람직하다.As the parent strain in the step (a), one excellent strain stored at 4 ° C. in a PDA (Potato dextrose agar) medium state was used at 25 ° C. in a shaker incubator using PDB (Potato dextrose broth) medium in an Erlenmeyer flask. It can be used to maintain a constant temperature and after 7 to 9 days incubation process. At this time, the amount of mycelia to be added to the inoculum is preferably about 0.5% (w / v) based on the amount of the solution to be cultured. Since the content of extracellular polysaccharides does not increase as the amount of mycelia is high (% / 100ml), the medium composition is a selective culture condition that forms the highest content of extracellular polysaccharides rather than the best nutritional ratio and environmental conditions for growth of the mycelia. It is preferable to apply.
상기 배양액은 균사체와 수용액으로 분리 정제할 수 있다. 상기 분리 정제를 위해 원심분리기로 균사체를 제거한 용액을 다중필터프레스(Multi-Sheet Filter Press)와 진동원심막분리기(PALLSEP)로 반복하여 정제한 후 1분간 자외선(UV)을 조사할 수 있다. 또한, 용액은 산소를 제거한 후 밀봉 보관하는 것이 필요한데, 이는 용액속에 균사가 존재할 경우 산소에 의해 균사가 성장하여 유효성분의 함량에 변화를 가져오기 때문이다.The culture solution can be separated and purified into a mycelium and an aqueous solution. For the separation and purification, the solution from which the mycelium is removed by centrifugation may be repeatedly purified using a multi-sheet filter press and a vibration centrifugal separator (PALLSEP), and then irradiated with ultraviolet (UV) light for 1 minute. In addition, the solution needs to be kept sealed after removing oxygen, because if the mycelium is present in the solution, the mycelium grows by oxygen, which brings about a change in the content of the active ingredient.
상기 (b) 단계에서는 상기 (a) 단계에서 제조된 균사체 배양액을 진공건조 또는 동결건조시켜 분말화할 수 있다. 상기의 건조는 유효물질의 소멸을 방지하기 위해 40℃ 이하의 온도, 바람직하게는 30℃ 이하의 온도에서 48~96시간 동안 수행되는 것이 바람직하다. 그리고 (b) 단계에서의 건조는 증발온도를 상대적으로 높게 설정하는 진공건조기보다 진공동결건조기를 사용하는 것이 유효물질 함량 변화가 최소화되므로 바람직하다.In step (b), the mycelia culture solution prepared in step (a) may be powdered by vacuum drying or lyophilization. The drying is preferably carried out for 48 to 96 hours at a temperature of 40 ℃ or less, preferably 30 ℃ or less in order to prevent the disappearance of the active material. And drying in step (b) is preferable to use a vacuum freeze dryer rather than a vacuum dryer to set the evaporation temperature relatively high because the change in the effective material content is minimized.
상기 (c) 단계에서는 (b) 단계에서 얻은 균사체 배양액 건조분말을 용매로 추출한 후 본 발명에 따른 조성물의 유효성분인 세포외다당체를 분리, 제조한다. 구체적으로, 건조 분말 5g에 증류수 100 mL을 첨가하여 잘 현탁한 후, 원심분리(8,000 rpm, 20 min)하여 이의 상등액에 그 양의 2~3배에 해당하는 추출용매를 첨가하고 냉장고(4℃)에 넣어 12시간 정치시킬 수 있다. 상기의 정치물에서 상등액만을 다시 원심분리(8,000 rpm, 20 min)한 후, 침전물을 회수하여 조(crude) 세포외다당체를 제조할 수 있다. 상기 조 세포외다당체를 30℃ 이하에서 진공동결건조하는 것이 바람직하다. In the step (c), after extracting the dry powder of the mycelium culture medium obtained in step (b) with a solvent to separate and prepare an extracellular polysaccharide which is an active ingredient of the composition according to the present invention. Specifically, 100 g of dry powder was added and 100 mL of distilled water was suspended, followed by centrifugation (8,000 rpm, 20 min) to add an extraction solvent corresponding to 2 to 3 times the amount of the supernatant thereof and a refrigerator (4 ° C). ) Can be left for 12 hours. After centrifugation (8,000 rpm, 20 min) again only the supernatant from the stationary material, the precipitate may be recovered to prepare crude extracellular polysaccharide. It is preferable to freeze-dry the crude extracellular polysaccharide at 30 ° C or lower.
상기 추출용매는 물, 에탄올, 메탄올, 아세톤, 부탄올 및 에틸아세테이트로 이루어진 군에서 선택되는 용매 또는 이들의 혼합용매일 수 있으며, 바람직하게는, 물 또는 50%(w/w)~80%(w/w)의 에탄올 수용액일 수 있다.The extraction solvent may be a solvent selected from the group consisting of water, ethanol, methanol, acetone, butanol and ethyl acetate or a mixed solvent thereof, preferably water or 50% (w / w) to 80% (w) / w) aqueous ethanol solution.
본 발명에 따른 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는 신경안정용 조성물에는 통상적으로 사용되는 적절한 담체, 부형제 및 희석제가 더 포함될 수 있다.Extracellular polysaccharide produced by the seriporia laccerata according to the present invention; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Alternatively, the neurostable composition containing the extract of the mycelium culture medium as an active ingredient may further include appropriate carriers, excipients, and diluents commonly used.
상기 세포외다당체는 조성물 총 중량에 대하여 0.1 내지 80 중량%, 바람직하게는 0.1 내지 50 중량%로 포함될 수 있으며, 세리포리아 락세라타의 균사체 배양액, 이의 건조분말 또는 추출물은 상기 세포외다당체의 함량에 해당하는 양으로 적절히 포함될 수 있다. 그러나, 가장 바람직한 세포외다당체 또는 이를 포함하는 배양액, 이의 건조분말 또는 추출물의 유효 함량은 조성물의 사용방법 및 목적에 따라 적절히 조절될 수 있다.The extracellular polysaccharide may be included in 0.1 to 80% by weight, preferably 0.1 to 50% by weight based on the total weight of the composition, the mycelium culture medium, dry powder or extract thereof of the Seriphoria laccerata content of the extracellular polysaccharide It may be appropriately included in the amount corresponding to. However, the effective amount of the most preferred extracellular polysaccharide or the culture solution containing the same, its dry powder or extract can be appropriately adjusted according to the method of use and purpose of the composition.
본 발명에 따른 조성물은 각각 통상의 방법에 따라 제형화하여 사용될 수 있다. 적합한 제형으로는 정제, 환제, 산제, 과립제, 당의정, 경질 또는 연질의 캡슐제, 용액제, 현탁제 또는 유화액제, 주사제, 좌제 등이 있으나, 이에 한정되는 것은 아니다. The compositions according to the invention can each be formulated and used according to conventional methods. Suitable formulations include, but are not limited to, tablets, pills, powders, granules, dragees, hard or soft capsules, solutions, suspensions or emulsions, injections, suppositories, and the like.
본 발명에 따른 조성물은 약학적으로 불활성인 유기 또는 무기 담체를 이용하여 적합한 제형으로 제조할 수 있다. 즉, 제형이 정제, 코팅된 정제, 당의정 및 경질 캡슐제인 경우 락토스, 수크로스, 전분 또는 그 유도체, 탈크, 칼슘 카보네이트, 젤라틴, 스테아르산 또는 그 염을 사용할 수 있다. 또한, 제형이 연질 캡슐제인 경우에는 식물성 오일, 왁스, 지방, 반고체 및 액체의 폴리올이 사용 가능하다. 또한, 제형이 용액 또는 시럽 형태인 경우에는 물, 폴리올, 글리세롤, 및 식물성 오일 등이 사용될 수 있다.The composition according to the invention can be prepared in a suitable formulation using a pharmaceutically inert organic or inorganic carrier. That is, lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof may be used when the formulation is a tablet, coated tablet, dragee and hard capsule. In addition, when the formulation is a soft capsule, polyols of vegetable oils, waxes, fats, semisolids and liquids can be used. In addition, water, polyols, glycerol, vegetable oils and the like can be used when the formulation is in the form of a solution or syrup.
본 발명에 따른 조성물은 상기의 담체외에도 보존제, 안정화제, 습윤제, 유화제, 용해제, 감미제, 착색제, 삼투압 조절제, 산화방지제 등을 더 포함할 수 있다.The composition according to the present invention may further include a preservative, a stabilizer, a wetting agent, an emulsifier, a solubilizer, a sweetener, a colorant, an osmotic agent, an antioxidant, and the like in addition to the above carrier.
본 발명에 따른 조성물의 투여방법은 제형에 따라 용이하게 선택될 수 있으며, 경구 또는 비경구 투여될 수 있다. 투여량은 환자의 나이, 성별, 체중, 병증의 정도, 투여경로에 따라 달라질 수 있으나, 일반적으로 유효성분인 세포외다당체를 기준으로 5 내지 500mg/kg의 양, 바람직하게는 100 내지 250mg/kg의 양을 1일 1회 내지 3회로 나누어 투여할 수 있다. 그러나, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The method of administering the composition according to the present invention can be easily selected according to the dosage form, and can be administered orally or parenterally. The dosage may vary depending on the age, sex, weight, severity, and route of administration of the patient, but is generally in an amount of 5 to 500 mg / kg, preferably 100 to 250 mg / kg, based on the extracellular polysaccharide as an active ingredient. The amount of may be administered once to three times a day. However, the dosage does not limit the scope of the invention in any aspect.
본 발명에 따른 조성물은 우수한 신경안정 효과를 제공할 뿐만 아니라 약물에 의한 독성 및 부작용도 거의 없어 신경안정용 목적으로 장기간 복용시에도 안심하고 사용할 수 있다. 따라서, 본 발명의 조성물은 신경안정을 필요로 하는 질환, 예를 들어, 우울증, 불안증, 수면 장애, 주의력 결핍/과잉행동 장애(ADHD) 등의 예방 및 치료를 위해 사용될 수 있다.The composition according to the present invention not only provides an excellent neurostable effect, but also has little toxicity and side effects due to the drug, so that it can be used with confidence even for long term administration for neurostable purposes. Thus, the compositions of the present invention can be used for the prevention and treatment of diseases requiring neurostable, such as depression, anxiety, sleep disorders, attention deficit / hyperactivity disorder (ADHD) and the like.
또한, 본 발명은 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는 신경안정 효능을 갖는 건강기능식품을 제공한다.In addition, the present invention is an extracellular polysaccharide produced by Ceriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a health functional food having neurostable efficacy containing the extract of the mycelia culture medium as an active ingredient.
본 발명에 따른 건강기능식품은 분말, 과립, 정제, 캡슐 또는 음료의 형태일 수 있고, 캔디, 초콜릿, 음료, 껌, 차, 비타민복합체, 건강보조식품 등일 수 있다.The health functional food according to the present invention may be in the form of powder, granules, tablets, capsules or beverages, and may be candy, chocolate, beverages, gums, teas, vitamin complexes, health supplements, and the like.
이때, 상기 식품 중의 본 발명에 따른 세포외다당체 또는 이를 포함하는 균사체 배양액, 이의 건조분말 또는 추출물은 일반적으로 전체 식품 중량의 0.01 내지 50 중량%, 바람직하게는 0.1 내지 20 중량%로 포함될 수 있고, 건강 음료 조성물의 경우 100ml를 기준으로 0.02 내지 10g, 바람직하게는 0.3 내지 1g의 비율로 포함될 수 있다. At this time, the extracellular polysaccharide according to the present invention in the food or the mycelia culture solution comprising the same, dried powder or extract thereof may generally be included in 0.01 to 50% by weight, preferably 0.1 to 20% by weight of the total food weight, In the case of a health beverage composition may be included in a ratio of 0.02 to 10g, preferably 0.3 to 1g based on 100ml.
상기 식품은 본 발명의 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물과 함께 식품학적으로 허용가능한 식품 보조 첨가제를 더 포함할 수 있다.The food is an extracellular polysaccharide produced by the seriporia laccerata of the present invention; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it may further include a food supplement acceptable food additive with the extract of the mycelia culture medium.
본 발명은 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 신경안정을 필요로 하는 대상에 투여하는 것을 포함하는, 신경안정방법을 제공한다.The present invention is an extracellular polysaccharide produced by the seriporia lacserata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a neurostable method comprising administering the extract of the mycelium culture to a subject in need of neurostable.
상기 신경안정을 필요로 하는 대상은 포유류 동물일 수 있고, 보다 구체적으로는 인간일 수 있다.The subject requiring neurostable may be a mammalian animal, and more specifically, a human.
또한, 본 발명은 신경안정을 위한 약제의 제조에 사용하기 위한, 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물의 용도를 제공한다.The present invention also provides an extracellular polysaccharide produced by Ceriporia laccerata for use in the preparation of a medicament for neurostable; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or it provides a use of the extract of the mycelium culture.
상기 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물은 전술한 바와 같다.Extracellular polysaccharide produced by the seriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Alternatively, the extract of the mycelium culture solution is as described above.
또한, 상기 신경안정방법은 신경안정을 필요로 하는 질환, 예를 들어, 우울증, 불안증, 수면 장애, 주의력 결핍/과잉행동 장애(ADHD) 등의 예방 및 치료에 사용될 수 있다.In addition, the neurostable method can be used for the prevention and treatment of diseases requiring neurostable, for example, depression, anxiety, sleep disorders, attention deficit / hyperactivity disorder (ADHD).
이하, 본 발명을 하기 실시예에 의하여 더욱 상세하게 설명한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.
[실시예]EXAMPLE
제조예Production Example
1. One.
세리포리아Serifolia
락세라타Lakserata
배양액, 이의 건조분말, 추출물 및 Culture, dry powder thereof, extract and
세포외다Extracellular
당체(exopolysaccharide; 이하, "EPS"라 함)의 제조Preparation of exopolysaccharide (hereinafter referred to as "EPS")
1.1 세리포리아 락세라타 배양액의 제조1.1 Preparation of Ceriporia laccerata Cultures
경북 상주시에서 채취한 참나무 변제부 속에서 분리한 세리포리아 락세라타를 계대배양을 통해 모균을 육성하여, 이를 -80℃에 냉동보관하였고, 보관중인 균주를 PDA(Potato dextrose agar) 배지(87 플라스틱 배양구; Difco, Becton Dickinson and Company)에서 2 ~ 3회 계대 후 균주(이하 "PDA 배양균주"라 함)를 4℃ 냉장고에 보관하여 사용하였다. 그리고 삼각플라스크에 PDB(Potato dextrose broth) 배지(Difco, Becton Dickinson and Company) 600 ㎖를 조성한 후, 여기에 PDA 배양균주 1개를 넣고 25℃에서 8일간 진탕배양하여, PDB 배양균주를 수득하였다. Ceryporia laccerata isolated from oak reimbursements collected from Sangju, Gyeongbuk, were grown by subculture, and frozen and stored at -80 ° C. The stored strain was stored in PDA (Potato dextrose agar) medium (87). Plastic cultures: Difco, Becton Dickinson and Company) after 2-3 passages strains (hereinafter referred to as "PDA culture strain") were used by storing in a 4 ℃ refrigerator. Then, after preparing 600 ml of PDB (Potato dextrose broth) medium (Difco, Becton Dickinson and Company) in an Erlenmeyer flask, one PDA culture strain was added thereto, followed by shaking culture at 25 ° C. for 8 days to obtain a PDB culture strain.
이후 설탕 1.5 중량%, 포도당 0.5 중량%, 감자전분 0.5 중량%, 수수분 0.25 중량%, 대맥분 0.25 중량%, 대두분 0.75 중량%, 황산마그네슘(MgSO4) 0.05 중량%, 1인산칼륨(KH2PO4) 0.05 중량%, 2인산칼륨(K2HPO4) 0.05 중량% 및 잔량의 물을 포함하는 액체 배양 배지를 800 L 발효조에서 121℃의 공기를 1.5 kgf/㎠로 주입하여 20분간 살균한 후, 23℃로 냉각한 상태에서 스타터로 상기 PDB 배양균주 600 ㎖를 접종하고, 공기를 0.5 ~ 1.5 kgf/㎠으로 통기시키면서, 광원은 청색 LED, 조도는 0.5 LUX를 유지하며, 이산화탄소의 농도는 2,000 ppm으로 세리포리아 락세라타 균사체를 23℃의 항온에서 10일간 액체 배양함으로써 세리포리아 락세라타 균사체 배양액을 제조하였다.Since sugar 1.5% by weight, glucose 0.5% by weight, potato starch 0.5% by weight, water content 0.25% by weight, soy flour 0.25% by weight, soybean powder 0.75% by weight, magnesium sulfate (MgSO 4 ) 0.05% by weight, potassium phosphate (KH 2 PO 4 ) Sterilized for 20 minutes in a liquid culture medium containing 0.05% by weight, 0.05% by weight of potassium diphosphate (K 2 HPO 4 ) and the residual amount of water by injecting air at 121 ° C. at 1.5 kgf / cm 2 in an 800 L fermenter. After inoculating 600 ml of the PDB culture strain with a starter in a state of cooling to 23 ° C., while ventilating air at 0.5 to 1.5 kgf / cm 2, the light source maintains a blue LED, illuminance of 0.5 LUX, and a concentration of carbon dioxide. Was prepared by culturing the Ceriporia laccerata mycelium at 2,000 ppm for 10 days liquid culture at a constant temperature of 23 ℃.
1.2 세리포리아 락세라타 배양액 건조분말의 제조1.2 Preparation of Dry Powder of Ceriporia laccerata Culture
제조예 1.1에서 제조된 세리포리아 락세라타 균사체 배양액을 진공동결건조기로 25℃에서 72시간 동안 진공동결건조시켜 분말화함으로써, 세리포리아 락세라타 균사체 배양액의 건조분말을 제조하였다.The dry powder of the Ceriporia laccerata mycelium culture medium was prepared by pulverizing and drying the Ceriporia laccerata mycelium culture medium prepared in Preparation Example 1.1 at 25 ° C. for 72 hours using a vacuum freeze dryer.
1.3 세리포리아 락세라타 배양액 추출물의 제조1.3 Preparation of Ceriporia laccerata Culture Extract
제조예 1.2에서 제조된 세리포리아 락세라타 균사체 배양액의 건조분말 5g에 증류수 100 ㎖를 첨가하여 잘 현탁한 후, 8,000 rpm으로 20분 동안 원심분리한 다음 이의 상등액에 그 양의 2 ~ 3배에 해당하는 에탄올을 첨가하고 4℃에서 12 시간 정치시켰다. 이후 정치물에서 상등액을 취해 세리포리아 락세라타 균사체 배양액의 추출물을 제조하였다.100 ml of distilled water was added to 5 g of the dry powder of the Ceriporia laccerata mycelium culture medium prepared in Preparation Example 1.2, and then suspended well, centrifuged at 8,000 rpm for 20 minutes, and then 2 to 3 times the amount thereof to the supernatant thereof. Corresponding ethanol was added and left to stand at 4 ° C for 12 hours. Subsequently, the supernatant was taken from the stationary material to prepare an extract of the culture medium of the seriporia laccerata.
1.4 세리포리아 락세라타 배양액으로부터 EPS의 제조1.4 Preparation of EPS from Ceriporia laccerata Cultures
제조예 1.3에서 제조된 세리포리아 락세라타 균사체 배양액의 추출물을 다시 8,000 rpm으로 20분 동안 원심분리한 후, 침전물을 회수하여 조(crude) EPS를 얻었다. 상기 조 EPS를 진공동결건조기에서 25℃에서 72시간 진공동결건조시켜 세리포리아 락세라타에 의해 생산되는 EPS를 획득하였다.After centrifugation of the extract of the seriporia laccerata mycelium culture medium prepared in Preparation Example 1.3 again at 8,000 rpm for 20 minutes, the precipitate was recovered to obtain a crude EPS. The crude EPS was vacuum-dried at 25 ° C. for 72 hours in a vacuum freeze dryer to obtain EPS produced by Ceriporia laccerata.
실시예 1. EPS의 특성 평가 Example 1 . Characterization of EPS
1.1 1.1
겔투과Gel permeation
크로마토그래피(Gel Permeation Chromatography, Chromatography (Gel Permeation Chromatography,
GPCGPC
)를 이용한 EPS의 분자량 측정Molecular weight of EPS using
상기 제조예 1에서 제조한 EPS를 0.1 M Na2SO4/0.05 M NaN3(빙초산(glacial acetic acid)으로 pH를 4로 조정) 용액에 1%(w/v)가 되도록 녹인 다음, 4,000 rpm으로 0.5 시간 동안 원심분리 후 상층액만을 0.45 ㎛ 시린지 필터(syringe filter)로 여과하여 GPC로 분석하였다.The EPS prepared in Preparation Example 1 was dissolved in 0.1 M Na 2 SO 4 /0.05 M NaN 3 (adjust the pH to 4 with glacial acetic acid) to 1% (w / v), and then 4,000 rpm. After centrifugation for 0.5 hours, only the supernatant was filtered with a 0.45 μm syringe filter and analyzed by GPC.
구체적으로, GPC 분석조건은 검출기로 굴절지수를 이용하였으며, GPC 칼럼은 OHpak SB 805 HQ(Shodex, Japan)를 이용하였고, 이동상은 0.1 M Na2SO4/0.05 M NaN3(빙초산으로 pH를 4로 조정)을 사용하였으며, 이동상의 유속은 1.0 ㎖/분으로 흘려주었다. 표준곡선은 각기 다른 분자량(130 kDa, 400 kDa, 770 kDa 또는 1200 kDa)을 가진 덱스트란(American Polymer Corporation, USA)을 이용하여 작성하였으며, 굴절지수(refractive index, RI) 측정기 Knauer K-2310(Germany)를 이용하여 EPS의 분자량을 측정하였다. 측정 조건을 정리하면 하기 표 1과 같다.Specifically, GPC analysis conditions were used for the refractive index as a detector, GPC column was used OHpak SB 805 HQ (Shodex, Japan), mobile phase 0.1 M Na 2 SO 4 /0.05 M NaN 3 (with pH 4 as glacial acetic acid) The flow rate of the mobile phase was flowed at 1.0 mL / minute. Standard curves were prepared using Dextran (American Polymer Corporation, USA) with different molecular weights (130 kDa, 400 kDa, 770 kDa, or 1200 kDa), and Knauer K-2310 (refractive index (RI) measuring instrument). Germany) to determine the molecular weight of EPS. The measurement conditions are summarized in Table 1 below.
그 결과, 본 발명의 EPS의 분자량은 약 120 kDa로 나타났다.As a result, the molecular weight of EPS of the present invention was found to be about 120 kDa.
1.2 EPS의 당 및 단백질 함량 측정1.2 Determination of sugar and protein content in EPS
제조예 1에서 제조한 EPS를 2차 정제하고 단백질 가수분해 효소를 처리하여 당 및 단백질 함량을 측정하였다.The EPS prepared in Preparation Example 1 was second-purified and treated with proteolytic enzymes to determine sugar and protein content.
구체적으로, 1차 정제된 EPS(제조예 1에서 제조한 EPS)를 증류수에 녹이고 8,000 rpm으로 20분 동안 원심분리하여 상등액을 분리한 후, 분리된 상등액에 그 양의 2 ~ 3배에 해당하는 에탄올을 첨가하고 4℃ 냉장고에 넣어 12시간 정치시켰다. 이후 정치물에서 상등액만을 다시 8,000 rpm으로 20분 동안 원심분리한 후, 침전물을 회수하여 2차 정제된 EPS를 획득하였다. 상기 2차 정제된 EPS를 증류수에 용해시킨 후 단백질 가수분해 효소인 알칼레이즈(alcalase)를 0.5%(w/v)의 농도로 50℃에서 30분간 처리하였다.Specifically, the first purified EPS (EPS prepared in Preparation Example 1) is dissolved in distilled water and centrifuged at 8,000 rpm for 20 minutes to separate the supernatant, and the amount of the supernatant is 2-3 times the amount of the separated supernatant. Ethanol was added and placed in a 4 ° C. refrigerator for 12 hours. Thereafter, only the supernatant was again centrifuged at 8,000 rpm for 20 minutes in the stationary material, and the precipitate was recovered to obtain a second purified EPS. After dissolving the second purified EPS in distilled water, the proteolytic enzyme alcalase was treated at 50 ° C. for 30 minutes at a concentration of 0.5% (w / v).
이후 당 함량은 페놀-황산법(phenol-sulfuric acid method)에 의해 측정하였다. 구체적으로, 농도별로 희석한 시료 1 ㎖에 80%(v/v) 페놀을 25 ㎕ 첨가한 후 황산 2.5 ㎖를 첨가하고 실온으로 냉각하고 465 nm에서 흡광도를 측정하여 당 함량을 계산하였다. Since the sugar content was measured by the phenol-sulfuric acid method (phenol-sulfuric acid method). Specifically, 25 μl of 80% (v / v) phenol was added to 1 mL of the diluted sample, 2.5 mL of sulfuric acid was added, cooled to room temperature, and absorbance was measured at 465 nm to calculate sugar content.
또한, 단백질 함량은 BCA 방법(Smith PK et al., Analytical Biochemistry, 150(1):76-85, 1985)에 의해 측정되었고 표준품으로 소혈청 알부민을 사용하였다.In addition, protein content was measured by the BCA method (Smith PK et al. , Analytical Biochemistry , 150 (1): 76-85, 1985) and bovine serum albumin was used as a standard.
상술한 바와 같이 측정한 당 함량 및 단백질 함량은 하기 표 2에 나타냈으며, 당 함량은 45 ~ 51 중량%이고 단백질 함량은 33 ~ 34 중량%인 것으로 나타났다.The sugar content and protein content measured as described above are shown in Table 2 below, and the sugar content was found to be 45 to 51 wt% and the protein content was 33 to 34 wt%.
또한, EPS의 당 구성 분석 결과, EPS는 주로 만노오스, 갈락토오스 및 글루코오스를 함유하고 있는 것으로 나타났다.In addition, the results of the sugar composition analysis of EPS, EPS mainly contained mannose, galactose and glucose.
실시예Example
2. EPS의 신경안정 효과 검증 2. Verification of neurostable effect of EPS
세리포리아 락세라타 균사체 배양액으로부터 분리된 EPS의 신경안정 효과를 조사하기 위하여, 상기 제조예 1에서 제조된 EPS를 흰쥐의 태아 해마 신경조직에서 분리한 해마 단일 세포에 처리한 후 세포내 칼슘농도 변화를 측정하였다. 구체적으로, 임신 18일 내지 19일된 흰쥐의 태아로부터 해마 신경조직을 해부 현미경하에서 분리하여 0.25% 트립신(trypsin)을 첨가한 후 37℃에서 10분간 반응시켰다. 이어서, 상기 조직을 HBSS(Hanks' Balanced Salt Solution)로 수회 세척하여 트립신을 제거한 후 1ml 파이펫으로 해마세포를 단일세포로 분리하였다. 분리된 해마 단일 세포에 상기 제조예 1에서 제조된 EPS를 100 ug/mL의 농도로 처리한 후, 세포 내 칼슘 농도의 변화를 문헌(Dunlap K. et al., Trends Neurosci., Vol. 18, No. 2, pp.89-98, 1995)에 기재된 방법을 참조하여 측정하였다.In order to investigate the neurostable effect of EPS isolated from Ceriporia laccerata mycelium culture medium, intracellular calcium concentration after treatment of EPS prepared in Preparation Example 1 to hippocampal single cells isolated from fetal hippocampal neural tissues of rats The change was measured. Specifically, hippocampal neural tissues were isolated from fetuses of 18 to 19 days pregnant under a dissecting microscope and 0.25% trypsin was added and reacted at 37 ° C. for 10 minutes. Subsequently, the tissue was washed several times with HBSS (Hanks' Balanced Salt Solution) to remove trypsin, and the hippocampal cells were separated into single cells with a 1 ml pipette. After the isolated hippocampal single cells were treated with the EPS prepared in Preparation Example 1 at a concentration of 100 ug / mL, changes in intracellular calcium concentration were described in Dunlap K. et al., Trends Neurosci., Vol. 18, No. 2, pp. 89-98, 1995).
상기 세포내 칼슘 농도 변화를 표 3 및 도 1에 나타내었다.The intracellular calcium concentration change is shown in Table 3 and FIG.
상기 표 3에서 보는 바와 같이, 본 발명에 따른 EPS의 농도가 100 ug/mL일 때 해마 세포 내 칼슘 농도는 EPS 처리전과 비교하여 평균 38.282% (n=14) 감소하였다. 글루타메이트 수용체는 칼슘이 자유롭게 세포 속으로 들어올 수 있도록 하였고, 이때 신경세포가 칼슘에 만성적으로 과도하게 노출될 경우, 흥분성 신경전달 작용이 빠르게 일어나게 된다. 본 발명에 따른 EPS는 수용체에 위치한 이동통로에서 친화력이 낮은 길항제로 작용하면서 칼슘채널(Ca2
+ channel) 활성의 억제 및 칼슘 이온(Ca2+)의 세포 내 유입을 상당히 감소시킴으로써 글루타메이트 수용체의 활성을 감소시켰다. 따라서, 상기 결과는 본 발명에 따른 EPS가 글루타메이트(흥분성 신경전달물질) 수용체의 억제를 통해 신경안정 효과가 있음을 보여준다.As shown in Table 3, when the concentration of EPS according to the present invention is 100 ug / mL calcium concentration in hippocampal cells was reduced by an average of 38.282% (n = 14) compared to before the EPS treatment. Glutamate receptors allow calcium to enter the cell freely, where excitatory neurotransmission occurs rapidly when neurons are chronically overexposed to calcium. EPS according to the present invention is a calcium channel while acting on the flow channel in the receptor to the low affinity antagonists (Ca + 2 channel) suppressed and the calcium ion (Ca 2+) of the glutamate receptor activity by significantly reducing the inflow cells of the active Reduced. Thus, the results show that the EPS according to the present invention has a neurostable effect through inhibition of glutamate (exciting neurotransmitter) receptors.
Claims (13)
- 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는, 신경안정용 조성물.Extracellular polysaccharides produced by Ceriporia lacerata ; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or a neurostable composition containing the extract of the mycelia culture medium as an active ingredient.
- 제 1 항에 있어서,The method of claim 1,상기 세포외다당체는 40~60 중량%의 당과 30~40 중량%의 단백질을 포함하고 100~150 kDa의 분자량을 갖는 것을 특징으로 하는 조성물.The extracellular polysaccharide comprises a composition of 40 to 60% by weight of sugar and 30 to 40% by weight of protein and has a molecular weight of 100 ~ 150 kDa.
- 제 2 항에 있어서,The method of claim 2,상기 세포외다당체는 43~47 중량%의 당과 33~36 중량%의 단백질을 포함하고 115~125 kDa의 분자량을 갖는 것을 특징으로 하는 조성물.The extracellular polysaccharide comprises a composition of 43 to 47% by weight of sugar and 33 to 36% by weight of protein and has a molecular weight of 115 ~ 125 kDa.
- 제 2 항에 있어서,The method of claim 2,상기 당은 만노오스, 갈락토오스 및 글루코오스를 함유하는 것을 특징으로 하는 조성물.Wherein the sugar contains mannose, galactose and glucose.
- 제 1 항에 있어서,The method of claim 1,상기 세포외다당체가, The extracellular polysaccharide,(a) 세리포리아 락세라타 균사체를 액체 배양하여 세리포리아 락세라타 균사체 배양액을 제조하는 단계;(a) liquid culturing the Ceriporia laccerata mycelium to prepare a Ceriporia laccerata mycelium culture solution;(b) 세리포리아 락세라타 균사체 배양액을 건조시켜 분말화하는 단계; 및(b) drying and powdering the Ceriporia laccerata mycelium culture solution; And(c) 세리포리아 락세라타 균사체 배양액 분말을 용매로 추출한 후 이를 여과하고 감압 농축하는 단계를 포함하는 제조 방법에 의하여 제조된 것을 특징으로 하는 조성물.(C) a composition, characterized in that prepared by the manufacturing method comprising the step of extracting the seriporia laccerata mycelium culture powder with a solvent and filtration and concentration under reduced pressure.
- 제 5 항에 있어서, The method of claim 5, wherein상기 액체 배양을 위한 배지는 설탕, 포도당, 전분, 수수분, 대맥분, 대두분, 황산마그네슘(MgSO4), 1인산칼륨(KH2PO4), 2인산칼륨(K2HPO4) 및 물을 포함하고, 수소이온농도가 pH 4.5~6.0인 것을 특징으로 하는 조성물.The medium for culturing the liquid is sugar, glucose, starch, sorghum, soybean meal, soy flour, magnesium sulfate (MgSO 4 ), potassium phosphate (KH 2 PO 4 ), potassium diphosphate (K 2 HPO 4 ) and water To include, the composition characterized in that the hydrogen ion concentration is pH 4.5 ~ 6.0.
- 제 5 항에 있어서, The method of claim 5, wherein상기 액체 배양은 청색 LED 광원 하에서 수행되고, 이산화탄소의 농도를 1,000~2,000 ppm으로 유지하여 수행되는 것을 특징으로 하는 조성물.The liquid culture is carried out under a blue LED light source, characterized in that the composition is carried out by maintaining the concentration of carbon dioxide at 1,000 ~ 2,000 ppm.
- 제 1 항에 있어서, The method of claim 1,상기 세포외다당체는 조성물 총 중량에 대하여 0.1 내지 80 중량%로 포함되는 것을 특징으로 하는 조성물.The extracellular polysaccharide composition is characterized in that it comprises 0.1 to 80% by weight relative to the total weight of the composition.
- 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는, 신경안정 효능을 갖는 건강기능식품.Extracellular polysaccharide produced by Ceriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or health functional foods containing the extract of the mycelia culture medium as an active ingredient, neurostable efficacy.
- 제 9항에 있어서,The method of claim 9,상기 식품은 분말, 과립, 정제, 캡슐 또는 음료의 형태인 것을 특징으로 하는, 건강기능식품.The food is characterized in that the form of powder, granules, tablets, capsules or beverages, health functional foods.
- 제 9항에 있어서,The method of claim 9,상기 식품은 캔디, 초콜릿, 음료, 껌, 차, 비타민복합체, 건강보조식품 등인 것을 특징으로 하는, 건강기능식품.The food is a functional food, characterized in that candy, chocolate, beverages, gum, tea, vitamin complexes, health supplements and the like.
- 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물을 신경안정을 필요로 하는 대상에 투여하는 것을 포함하는, 신경안정방법.Extracellular polysaccharide produced by Ceriporia laccerata; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or administering an extract of the mycelium culture solution to a subject in need of neurostable.
- 신경안정을 위한 약제의 제조에 사용하기 위한, 세리포리아 락세라타에 의해 생산되는 세포외다당체; 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액; 상기 균사체 배양액의 건조분말; 또는 상기 균사체 배양액의 추출물의 용도.Extracellular polysaccharides produced by Ceriporia laccerata for use in the manufacture of a medicament for neurostable; Mycelium culture medium of Seriporia laccerata containing the extracellular polysaccharide; Dry powder of the mycelia culture medium; Or the use of an extract of the mycelium culture.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580059839.5A CN106998777B (en) | 2014-11-03 | 2015-11-03 | Composition for calming nerves containing exopolysaccharide produced by Ceriporia lacerata as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0151573 | 2014-11-03 | ||
KR1020140151573A KR101682096B1 (en) | 2014-11-03 | 2014-11-03 | Tranquilizer composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016072710A1 true WO2016072710A1 (en) | 2016-05-12 |
Family
ID=55909372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/011718 WO2016072710A1 (en) | 2014-11-03 | 2015-11-03 | Tranquilizing composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR101682096B1 (en) |
CN (1) | CN106998777B (en) |
WO (1) | WO2016072710A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10226494B2 (en) | 2014-11-27 | 2019-03-12 | Fugenbio Co., Ltd. | Antioxidant composition containing extracellular polysaccharide produced using Ceriporia lacerata as active ingredient |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101645652B1 (en) * | 2014-11-03 | 2016-08-08 | (주)퓨젠바이오농업회사법인 | Sexual function improvement composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100117918A (en) * | 2009-04-27 | 2010-11-04 | 강원대학교산학협력단 | The preparing method for natural gaba using serial fermentation of plant originated lactic acid bacteria with gaba-producing ability and protease-producing ability, and the food and beverage containing the natural gaba |
KR101031605B1 (en) * | 2010-11-11 | 2011-04-27 | 김병천 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
KR101207899B1 (en) * | 2009-12-30 | 2012-12-04 | (주)마린바이오프로세스 | The producing process of functional and fermented material containing taurine and GABA by fermentation with oyster |
WO2014112666A1 (en) * | 2013-01-18 | 2014-07-24 | (주) 퓨젠바이오농업회사법인 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
KR101444614B1 (en) * | 2013-08-01 | 2014-09-26 | 계명대학교 산학협력단 | Method for producing fermented material with high GABA by mixed culture of Ceriporia lacerata and Lactobacillus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103173357B (en) * | 2011-12-22 | 2015-11-25 | 高冬 | Tear wax pore fungi and uses thereof |
US20140193454A1 (en) * | 2013-01-09 | 2014-07-10 | Byoung Cheon KIM | Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient |
-
2014
- 2014-11-03 KR KR1020140151573A patent/KR101682096B1/en active IP Right Grant
-
2015
- 2015-11-03 WO PCT/KR2015/011718 patent/WO2016072710A1/en active Application Filing
- 2015-11-03 CN CN201580059839.5A patent/CN106998777B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100117918A (en) * | 2009-04-27 | 2010-11-04 | 강원대학교산학협력단 | The preparing method for natural gaba using serial fermentation of plant originated lactic acid bacteria with gaba-producing ability and protease-producing ability, and the food and beverage containing the natural gaba |
KR101207899B1 (en) * | 2009-12-30 | 2012-12-04 | (주)마린바이오프로세스 | The producing process of functional and fermented material containing taurine and GABA by fermentation with oyster |
KR101031605B1 (en) * | 2010-11-11 | 2011-04-27 | 김병천 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
WO2014112666A1 (en) * | 2013-01-18 | 2014-07-24 | (주) 퓨젠바이오농업회사법인 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
KR101444614B1 (en) * | 2013-08-01 | 2014-09-26 | 계명대학교 산학협력단 | Method for producing fermented material with high GABA by mixed culture of Ceriporia lacerata and Lactobacillus |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10226494B2 (en) | 2014-11-27 | 2019-03-12 | Fugenbio Co., Ltd. | Antioxidant composition containing extracellular polysaccharide produced using Ceriporia lacerata as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
CN106998777A (en) | 2017-08-01 |
KR101682096B1 (en) | 2016-12-02 |
CN106998777B (en) | 2021-06-04 |
KR20160051465A (en) | 2016-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO822995L (en) | NEW LIPID FRACTION, ITS PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THE FRACTION | |
WO2010058926A2 (en) | Pharmaceutical composition containing ginger extract or shogaol | |
WO2018139898A1 (en) | Composition for enhancing immunity, containing ginseng berry polysaccharides | |
WO2017061769A1 (en) | Composition for preventing alopecia or stimulating hair growth containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient | |
CN107007553A (en) | A kind of polysaccharide cholate liposome for being used to be administered orally and preparation method thereof | |
CN102552644A (en) | Anti-tumor use, preparation method and composition of garlic total polysaccharide | |
WO2016085290A1 (en) | Antioxidant composition containing extracellular polysaccharide produced using ceriporia lacerata as active ingredient | |
WO2016072710A1 (en) | Tranquilizing composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata | |
WO2017023070A1 (en) | Composition for promoting fatigue recovery containing, as an active ingredient, extracellular polysaccharides produced by ceriporia lacerate | |
WO2016072697A1 (en) | Blood pressure lowering composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata | |
KR20160008425A (en) | Composition for improvement of liver function comprising exopolysaccharide derived from ceriporia lacerata culture broth extracts as an active ingredient | |
WO2014046345A1 (en) | Method for isolating fraction having anti-inflammatory or osteoarthritis-inhibiting effects by using oyster shell chips | |
CN116948901B (en) | Application of Weissella antrum D-2 extracellular polysaccharide in inhibiting colon cancer cells | |
WO2017061819A1 (en) | Composition for improving blood circulation containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient | |
CN114699424A (en) | Novel application of bacteroides fragilis zwitterionic capsular polysaccharide or/and modified zwitterionic capsular polysaccharide | |
WO2016072713A1 (en) | Sexual function improving composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata | |
WO2017061787A1 (en) | Composition for relieving hangovers containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient | |
KR101737626B1 (en) | Composition for immunosuppression comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
WO2020004858A1 (en) | Diabetes-alleviating or antioxidant composition comprising yeast extract and method for preparing yeast extract | |
WO2014030913A1 (en) | Poly(4-hydroxybutyrate)-b-monomethoxy(polyethylene glycol) copolymer nanoparticles, production method for same and pharmaceutical composition for brain disorder treatment containing same as active ingredient | |
CN107182201B (en) | Pharmaceutical composition for preventing or treating cancer comprising exopolysaccharide produced by Ceriporia lacerata as active ingredient | |
WO2020017674A1 (en) | Pharmaceutical composition for alleviating eye fatigue, containing, as active ingredients, luteolin-7-o-diglucuronide and apigenin-7-o-diglucuronide isolated from perilla frutescens (l.) britton var. acuta (thunb.) kudo leaf extract | |
WO2014112665A1 (en) | Pharmaceutical composition and health functional food for preventing or treating steroid-induced diabetes | |
KR20070088940A (en) | Amaranthaceae extracts compositions for treating or preventing inflammatory diseases | |
US9717769B2 (en) | Method for protecting kidney function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15857082 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15857082 Country of ref document: EP Kind code of ref document: A1 |